2. Search Result
Search Result
Results for "

pulmonary+hypertension

" in MedChemExpress (MCE) Product Catalog:

40

Inhibitors & Agonists

1

Screening Libraries

1

Inhibitory Antibodies

7

Natural
Products

4

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0750
    Monocrotaline
    40+ Cited Publications

    Crotaline

    		 Others Infection Metabolic Disease Cancer
    Monocrotaline is an 11-membered macrocyclic pyrrolizidine alkaloid. Monocrotaline inhibits OCT-1 and OCT-2 with IC50s of 36.8 µM and 1.8 mM, respectively. Monocrotaline has antitumor activity and is cytotoxic to hepatocellular carcinoma cells. Monocrotaline is used to induce a model of pulmonary hypertension in rodents. [2][6][8].
    Monocrotaline
  • HY-14779
    Riociguat
    15+ Cited Publications

    BAY 632521

    		 Guanylate Cyclase Cardiovascular Disease
    Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.
    Riociguat
  • HY-A0126A
    Epoprostenol sodium
    1 Publications Verification

    Prostaglandin I2 sodium salt; Prostacyclin sodium salt; Flolan

    		 Endogenous Metabolite Apoptosis Cardiovascular Disease
    Epoprostenol sodium (Prostaglandin I2) sodium salt, the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH). Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation .
    Epoprostenol sodium
  • HY-148826
    Rovunaptabin

    ARC 183; BC 007

    		 G Protein-coupled Receptor Kinase (GRK) Cardiovascular Disease
    Rovunaptabin (ARC 183) is an aptamer, a single-stranded DNA molecule composed of 15 deoxynucleotides. It acts as a broad-spectrum neutralizer of pathogenic G-protein-coupled receptor autoantibodies. Rovunaptabin can be used in research related to cardiomyopathy and pulmonary hypertension .
    Rovunaptabin
  • HY-40136
    cis-4-Hydroxy-L-proline

    		Endogenous Metabolite Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension .
    cis-4-Hydroxy-L-proline
  • HY-11095
    NPS 2390

    		mGluR CaSR PI3K Akt mTOR Autophagy Apoptosis Bcl-2 Family Caspase Cardiovascular Disease Neurological Disease
    NPS 2390 is an allosteric antagonist of calcium-sensing receptor (CaSR) and mGluR1/5. NPS 2390 inhibits the PI3K/Akt/mTOR signaling pathway, reduces hypoxia-induced intracellular calcium elevation, decreases the expression of autophagy (autophagy) proteins, regulates the expression of phenotypic marker proteins, and inhibits the proliferation of pulmonary artery smooth muscle cells. NPS 2390 attenuates the endogenous apoptosis (apoptosis) pathway, increases the expression level of Bcl-2, downregulates the expression levels of Bax, cytochrome c and caspase-3, alleviates cerebral edema and improves neurological function in rat models. NPS 2390 can be used in studies related to hypoxic pulmonary hypertension, traumatic brain injury, stroke and pain .
    NPS 2390
  • HY-113111
    11,12-DiHETrE

    		Drug Metabolite Inflammation/Immunology
    11,12-DiHETrE is a dihydroxy fatty acid metabolite of Arachidonic Acid (HY-109590). 11,12-DiHETrE is converted to 11,12-DiHETrE under elevated soluble epoxide hydrolase (sEH) activity, a process closely related to inflammation and oxidative stress. 11,12-DiHETrE can serve as a single biomarker to differentiate between NAFL (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis). 11,12-DiHETrE can be used in studies on preterm birth, autism, and pulmonary hypertension .
    11,12-DiHETrE
  • HY-149316
    Smurf1-IN-1

    		E1/E2/E3 Enzyme Cardiovascular Disease
    Smurf1-IN-1 is an orally active and selective inhibitor of specific E3 ubiquitin protein ligase 1 (SMURF1) with an IC50 of 92 nM. Smurf1-IN-1 has significant efficacy in rats model of pulmonary hypertension .
    Smurf1-IN-1
  • HY-118010A
    (+)-Norfenfluramine hydrochloride

    d-Norfenfluramine hydrochloride

    		 5-HT Receptor Cardiovascular Disease
    (+)-Norfenfluramine hydrochloride, a major hepatic metabolite of (+)-fenfluramine, is a selective 5-HT2B receptor agonist (Ki: 11.2 nM). (+)-Norfenfluramine hydrochloride potently stimulates the hydrolysis of inositol phosphates and increases intracellular Ca 2+. (+)-Norfenfluramine hydrochloride can be used for the research of primary pulmonary hypertension and valvular heart disease .
    (+)-Norfenfluramine hydrochloride
  • HY-W131725
    (+)-Norfenfluramine

    d-Norfenfluramine

    		 5-HT Receptor Cardiovascular Disease
    (+)-Norfenfluramine a major hepatic metabolite of (+)-fenfluramine, is a selective 5-HT2B receptor agonist (Ki: 11.2 nM). (+)-Norfenfluramine potently stimulates the hydrolysis of inositol phosphates and increases intracellular Ca 2+. (+)-Norfenfluramine can be used for the research of primary pulmonary hypertension and valvular heart disease .
    (+)-Norfenfluramine
  • HY-130581
    Lipid X

    		Bacterial Cardiovascular Disease Inflammation/Immunology
    Lipid X is a 2,3-diacylglucosamine-1-phosphate that serves as the monosaccharide precursor of lipid A, possessing both LPS antagonist and weak agonist activities. Lipid X exerts protective effects by inhibiting tumor necrosis factor production, monocyte procoagulant activity, and neutrophil priming. Lipid X may induce transient pulmonary hypertension, neutropenia, and mild pyrogenic effects in laboratory animals. Lipid X has low toxicity and no in vitro antibacterial activity, but it significantly reduces mortality following Gram-negative bacterial infection and endotoxin exposure. Lipid X tends to accumulate in liver tissue, binds to circulating cellular components, and can be converted to lipid Y through transesterification. Lipid X can be used in research on Gram-negative bacterial sepsis, endotoxemia, and associated pulmonary hypertension .
    Lipid X
  • HY-N9279
    Dehydromonocrotaline

    Monocrotaline pyrrole; MCTP; 3,8-Didehydromonocrotaline

    		 Endogenous Metabolite Cardiovascular Disease Cancer
    Dehydromonocrotaline is a mitochondrial respiratory chain complex I NADH oxidase inhibitor, with a IC50 of 62.06 μM and a Ki of 8.1 μM in rats. Dehydromonocrotaline exerts non-competitive inhibitory effects by modifying cysteine thiol groups on complex I, and does not bind to the NADH-binding site. Dehydromonocrotaline dissipates mitochondrial membrane potential and reduces ATP levels. Dehydromonocrotaline can be used in studies related to hepatotoxicity, pulmonary hypertension and liver tumors .
    Dehydromonocrotaline
  • HY-123744
    PD-156707

    		Endothelin Receptor Cardiovascular Disease Neurological Disease
    PD-156707 is an orally active, nonpeptide and selective Endothelin-A receptor antagonist. PD-156707 binds to human ET-A and ET-B receptors with Ki values of 0.17 nM and 133.8 nM, respectively. PD-156707 shows reversal of established chronic hypoxic pulmonary hypertension in rats. PD-156707 can be used for the study of diseases associated with abnormal ET-A receptor activation, particularly pulmonary hypertension, stroke, and heart failure .
    PD-156707
  • HY-105408A
    Fandosentan potassium

    		Endothelin Receptor Cytochrome P450 Cardiovascular Disease
    Fandosentan potassium is a potent endothelin A receptor (ETAR) antagonist. Fandosentan potassium inhibits CYP2C9 and CYP3A4 activities with IC50 values of 39.6 and 21.6 μM, respectively. Fandosentan potassium reverses the hypoxic pulmonary vasoconstriction in the perinatal lamb. Fandosentan potassium can be used for pulmonary hypertension research [1][2].
    Fandosentan potassium
  • HY-40136S
    cis-4-Hydroxy-L-proline-d3

    		Isotope-Labeled Compounds Endogenous Metabolite Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    cis-4-Hydroxy-L-proline-d3 is the deuterium labeled cis-4-Hydroxy-L-proline (HY-40136). cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension .
    cis-4-Hydroxy-L-proline-d3
  • HY-168985
    Mirivadelgat

    		Aldehyde Dehydrogenase (ALDH) Cancer
    Mirivadelgat is an activator of aldehyde dehydrogenase 2 activator. Mirivadelgat is promising for research of interstitial lung disease-pulmonary hypertension and cancers .
    Mirivadelgat
  • HY-165587
    BM-573

    		Prostaglandin Receptor Cardiovascular Disease
    BM-573 is an orally active dual thromboxane A₂ (TXA₂) modulator with an IC50 of 1.3 nM. BM-573 possesses both thromboxane synthase (TxAS) inhibition and thromboxane receptor (TP) antagonistic effects. BM-573 can completely inhibit platelet aggregation induced by Arachidonic acid (HY-109590) or U-46619 (TXA₂ analogues). BM-573 completely blocks the generation of TXB₂ (the stable metabolite of TXA₂) in human platelets and does not inhibit cyclooxygenase (COX-1/COX-2), thus avoiding interference with other prostaglandin synthesis. BM-573 has an inhibitory effect on U-46619-induced contractions in rat gastric fundus smooth muscle (ED₅₀ = 4.2 μM), but has no effect on contractions caused by PGE₂, PGF₂α, or PGI₂. BM-573 can be used in the study of atherosclerosis, myocardial infarction, pulmonary hypertension and shock .
    BM-573
  • HY-14779R
    Riociguat (Standard)

    BAY 632521 (Standard)

    		 Reference Standards Guanylate Cyclase Cardiovascular Disease
    Riociguat (Standard) is the analytical standard of Riociguat. This product is intended for research and analytical applications. Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.
    Riociguat (Standard)
  • HY-14779S3
    Riociguat-d3

    BAY 632521-d3

    		 Isotope-Labeled Compounds Guanylate Cyclase Cardiovascular Disease
    Riociguat-d3 (BAY 632521-d3) is deuterium labeled Riociguat. Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.
    Riociguat-d3
  • HY-14779S
    Riociguat-13C,d6

    BAY 632521-13C,d6

    		 Isotope-Labeled Compounds Cardiovascular Disease
    Riociguat- 13C,d6 is the 13C and deuterium labeled Riociguat (HY-14779). Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.
    Riociguat-13C,d6
  • HY-N16469
    Ruscin

    Ruscoponticoside D; Neoruscine

    		 Others Cardiovascular Disease Inflammation/Immunology
    Ruscin (Ruscoponticoside D; Neoruscine) is steroidal saponin found in Butcher’s Broom. Ruscin has multiple bioactivities and possesses a variety of pharmacological activities, including anti-inflammatory properties, platelet aggregation inhibition, pulmonary hypertension lowering properties, acute lung injury alleviation .
    Ruscin
  • HY-145413
    BRD2889

    		Glutathione S-transferase Cancer
    BRD2889 is an analog of the alkaloid piperlongumine. BRD2889 is a robust modulator of the GSTP1-ISCU axis in pulmonary hypertension (PH) . BRD2889 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    BRD2889
  • HY-A0126AR
    Epoprostenol sodium (Standard)

    Prostaglandin I2 sodium salt (Standard); Prostacyclin sodium salt (Standard); Flolan (Standard)

    		 Reference Standards Endogenous Metabolite Cardiovascular Disease
    Epoprostenol (sodium) (Standard) is the analytical standard of Epoprostenol (sodium). This product is intended for research and analytical applications. Epoprostenol sodium (Prostaglandin I2 (sodium salt)), the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH) . Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation .
    Epoprostenol sodium (Standard)
  • HY-167891
    GPD-1116

    		Phosphodiesterase (PDE) Apoptosis Inflammation/Immunology
    GPD-1116 is an orally active Phosphodiesterase (PDE) 4 and PDE1 inhibitor. GPD-1116 can reduce smoke-induced apoptosis of lung cells. GPD-1116 is effective in several disease models in animals, including emphysema, acute lung injury, chronic obstructive pulmonary disease (COPD), asthma and pulmonary hypertension .
    GPD-1116
  • HY-N0750R
    Monocrotaline (Standard)

    Crotaline (Standard)

    		 Reference Standards Others Metabolic Disease Cancer
    Monocrotaline is an 11-membered macrocyclic pyrrolizidine alkaloid. Monocrotaline inhibits OCT-1 and OCT-2 with IC50s of 36.8 µM and 1.8 mM, respectively. Monocrotaline has antitumor activity and is cytotoxic to hepatocellular carcinoma cells. Monocrotaline is used to induce a model of pulmonary hypertension in rodents. .
    Monocrotaline (Standard)
  • HY-103459
    CI-1020

    PD156707

    		 Endothelin Receptor Cardiovascular Disease
    CI-1020 (PD156707) is an orally active and selective antagonist targeting endothelin (ETA) with an IC50 value of 0.3 nM. CI-1020 blocks intimal hyperplasia in human saphenous veins completely in organ culture. CI 1020 inhibits hypoxic pulmonary hypertension and blocks ET-1-induced pressor responses following oral administration .
    CI-1020
  • HY-142698
    SGC agonist 2

    		Guanylate Cyclase Cardiovascular Disease
    SGC agonist 2 is a potent agonist of soluble guanylate cyclase (SGC). Soluble guanylate cyclase is a key signal transduction enzyme in the NO-sGC-cGMP signaling pathway. SGC agonist 2 has the potential for the research of cardiovascular disease (heart failure, pulmonary hypertension, angina, myocardial infarction) and fibrotic diseases (renal fibrosis, systemic sclerosis) (extracted from patent WO2021219088A1, compound 031) .
    SGC agonist 2
  • HY-19244
    JTV-506

    		Potassium Channel Cardiovascular Disease
    JTV-506 is a potent ATP-sensitive potassium channel opener. JTV-506 inhibits Histamine (HY-B1204)-induced contraction of tracheal smooth muscle by activation of KATP channels. JTV-506 attenuates pulmonary vascular tone through its direct action on vascular smooth muscle cells. JTV-506 can be used for pulmonary hypertension research .
    JTV-506
  • HY-W700639
    Tolafentrine

    		Phosphodiesterase (PDE) Neurological Disease
    Tolafentrine, a dual-selective phosphodiesterase 3/4 (PDE3/4) inhibitor, has been shown to have significant acute and chronic effects in a unilateral diacetamide-induced rat pulmonary hypertension model. Experiments show that long-term administration can significantly alleviate all unilateral bisacetamide-induced hemodynamic and gas exchange abnormalities, reduce right ventricular hypertrophy, and normalize pulmonary vascular remodeling changes .
    Tolafentrine
  • HY-B0130R
    Perindopril (Standard)

    S-9490 (Standard)

    		 Angiotensin-converting Enzyme (ACE) NF-κB STAT Sirtuin Reference Standards Cardiovascular Disease Neurological Disease Cancer
    Perindopril (Standard) is the analytical standard of Perindopril. This product is intended for research and analytical applications. Perindopril (S-9490) is an orally available, long-acting angiotensin-converting enzyme (ACE) inhibitor. Perindopril inhibits inflammatory cell influx and intimal thickening, preserving elastin on the inside of the aorta. Perindopril effectively inhibits experimental abdominal aortic aneurysm (AAA) formation in a rat model and reduces pulmonary vasoconstriction in rats with pulmonary hypertension .
    Perindopril (Standard)
  • HY-B0130S1
    Perindopril-d5

    S-9490-d5

    		 Isotope-Labeled Compounds Sirtuin Angiotensin-converting Enzyme (ACE) NF-κB STAT Cardiovascular Disease Neurological Disease Cancer
    Perindopril-d5 (S-9490-d5) is deuterium labeled Perindopril. Perindopril (S-9490) is an orally available, long-acting angiotensin-converting enzyme (ACE) inhibitor. Perindopril inhibits inflammatory cell influx and intimal thickening, preserving elastin on the inside of the aorta. Perindopril effectively inhibits experimental abdominal aortic aneurysm (AAA) formation in a rat model and reduces pulmonary vasoconstriction in rats with pulmonary hypertension .
    Perindopril-d5
  • HY-120152
    SLP7111228

    		SphK Interleukin Related TNF Receptor Cardiovascular Disease Inflammation/Immunology
    SLP7111228 is a selective sphingosine kinase 1 (SphK1) inhibitor and anti-inflammatory agent. SLP7111228 selectively inhibits SphK1 and reduces the production of sphingosine-1-phosphate. SLP7111228 decreases lipopolysaccharide-induced TNFα and IL-1β levels. SLP7111228 alleviates obliterative pulmonary arteriopathy, increases cardiac index and decreases total pulmonary vascular resistance index. SLP7111228 can be used in research related to neuroinflammatory diseases and pulmonary hypertension .
    SLP7111228
  • HY-40136R
    cis-4-Hydroxy-L-proline (Standard)

    		Reference Standards Endogenous Metabolite Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    cis-4-Hydroxy-L-proline (Standard) is the analytical standard of cis-4-Hydroxy-L-proline (HY-40136). This product is intended for research and analytical applications. cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension .
    cis-4-Hydroxy-L-proline (Standard)
  • HY-105341
    UK 343664

    		Phosphodiesterase (PDE) Cardiovascular Disease
    UK 343664 is a potent, orally active and selective PDE5 inhibitor. UK 343664 partially reverses Thromboxane-induced pulmonary hypertension .
    UK 343664
  • HY-124074
    S-3448

    		Guanylate Cyclase Cardiovascular Disease
    S-3448 is a derivative of Ataciguat (HY-17500). S-3448 is a Soluble guanylate cyclase (sGC) agonist. S-3448 activates both the haem-containing and the haem-deficient form of sGC without depending on NO and heme. S-3448 can be used for cardiovascular diseases such as arterial hypertension and pulmonary hypertension research .
    S-3448
  • HY-P991758
    Anti-Mouse PDGFRα Antibody (APA5)

    		PDGFR Cardiovascular Disease
    Anti-Mouse PDGFRα Antibody (APA5) reacts with mouse PDGFRα. Anti-Mouse PDGFRα Antibody (APA5) can be used to block PDGFRα in vitro and in vivo. Anti-Mouse PDGFRα Antibody (APA5) can be used for the study of pulmonary hypertension. Recommend Isotype Controls: Rat IgG2a kappa, Isotype Control (HY-P990679) .
    Anti-Mouse PDGFRα Antibody (APA5)
  • HY-19080
    SC-45662

    		Lipoxygenase Inflammation/Immunology
    SC-45662 is a 5-lipoxygenase inhibitor. SC-45662 inhibits the response of monocytes to phytohemagglutinin (PHA). SC-45662 inhibits superoxide production in neutrophils. SC-45662 slows early changes in lung mechanics and pulmonary hypertension in a sheep model of impaired lung function. SC-45662 can be used in research on diseases of the immune system, respiratory system, etc .
    SC-45662
  • HY-120152A
    SLP7111228 hydrochloride

    		SphK Interleukin Related TNF Receptor Cardiovascular Disease Inflammation/Immunology
    SLP7111228 hydrochloride is a selective sphingosine kinase 1 (SphK1) inhibitor and anti-inflammatory agent. SLP7111228 hydrochloride selectively inhibits SphK1 and reduces the production of sphingosine-1-phosphate. SLP7111228 hydrochloride decreases lipopolysaccharide-induced TNFα and IL-1β levels. SLP7111228 hydrochloride alleviates obliterative pulmonary arteriopathy, increases cardiac index and decreases total pulmonary vascular resistance index. SLP7111228 hydrochloride can be used in research related to neuroinflammatory diseases and pulmonary hypertension .
    SLP7111228 hydrochloride
  • HY-183644
    LNO 9

    		Lysyl Oxidase Cardiovascular Disease
    LNO 9 is an orally active LOXL2 inhibitor and NO donor, with an IC50 of 0.17 μM against human LOXL2. LNO 9 competitively binds to the LTQ cofactor of LOXL2 to form an irreversible complex, thereby inhibiting collagen oxidation and abnormal cross-linking. LNO 9 releases nitric oxide (NO) to increase cGMP levels in pulmonary artery smooth muscle cells. LNO 9 inhibits hypoxia-induced collagen modification and possesses vasodilatory activity. LNO 9 ameliorates right ventricular hypertrophy and pulmonary artery medial thickness in rat models induced by hypoxia and Monocrotaline (HY-N0750), and can be used for research on pulmonary hypertension .
    LNO 9
  • HY-124487
    GK-136901

    		NADPH Oxidase TGF-β Receptor Reactive Oxygen Species (ROS) p38 MAPK Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    GK-136901 is an orally active, dual Nox1/Nox4 NADPH oxidase inhibitor with a Ki of 160 nM for Nox1 and 165 nM for Nox4. GK-136901 potently blocks high glucose-induced intracellular reactive oxygen species production, p38-MAPK phosphorylation, and upregulation of TGF-β1/2 and fibronectin (fibronectin) in renal cells. GK-136901 also inhibits the proliferation of mouse pulmonary vascular cells under hypoxic conditions. GK-136901 is applicable to the research on the pathogenesis of type 2 diabetic nephropathy, high glucose-related renal lesions and pulmonary hypertension .
    GK-136901

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: